Corticotropin gel - Mallinckrodt

Drug Profile

Corticotropin gel - Mallinckrodt

Alternative Names: Acthar; Acthar Gel; Adrenocorticotropin gel - Mallinckrodt; H.P. Acthar Gel; Repository corticotropin injection - Mallinckrodt

Latest Information Update: 15 Jul 2017

Price : $50

At a glance

  • Originator Aventis Pharmaceuticals
  • Developer Mallinckrodt plc
  • Class Anterior pituitary hormones; Antiepileptic drugs; Corticosteroids; Hypothalamic hormones
  • Mechanism of Action Corticotropin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Infantile spasms
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adrenal cortex disorders; Ankylosing spondylitis; Infantile spasms; Juvenile rheumatoid arthritis; Membranous glomerulonephritis; Multiple sclerosis; Nephrotic syndrome; Ocular inflammation; Polymyositis; Psoriatic arthritis; Rheumatoid arthritis; Sarcoidosis; Systemic lupus erythematosus
  • Phase II Amyotrophic lateral sclerosis
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 26 Jun 2017 Discontinued - Phase-II for Diabetic nephropathies in USA (SC)
  • 22 Jun 2017 Launched for Ocular inflammation in USA (SC), before June 2017
  • 14 Jun 2017 Corticotropin gel - Mallinckrodt receives Fast Track designation for Amyotrophic lateral sclerosis [SC,Injection] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top